Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Betsy Davis

Betsy Davis

Senior Strategic Marketing Manager

Connect with Betsy Davis on LinkedIn
Follow Betsy Davis on Twitter
Website:

About the author:

Betsy’s entire marketing career has exclusively focused on the STEM market, with a distinct emphasis on Pharma. During her tenure with Elsevier’s Corporate R&D group, she has managed market segmentation for the pharma and life sciences industry, and launched and manages The Hive, a partnership with a select group of biotech and pharmaceutical start-ups focused on early stage innovation in drug discovery and development. The program promotes collaboration and inspiration across the Pharma & Life Sciences industry. Prior to launching her marketing career, Betsy worked as a management consultant focused on strategy implementation. She holds an MBA from the University of Michigan’s Ross School of Business and a BA from Barnard College of Columbia University.


Posts by Betsy Davis

Pills Have Gone Digital

Posted on November 24th, 2017 in Pharma R&D

Paranoiacs and conspiracy theorists beware – the digital pill is here. The U.S. Food and Drug Administration announced on November 13 that it had approved Abilify MyCite (aripiprazole tablets with sensors), the first drug in America to have a digital ingestion tracking system. Continue reading “Pills Have Gone Digital” »

Seeking Other Perspectives to Tease Out New Innovations

Posted on November 22nd, 2017 in Pharma R&D

On October 24, Astellas Oncology announced the five finalists in its C3 Prize competition, chosen from over 160 entrants who submitted their ideas on how to improve the cancer care experience through non-medicine innovations. Continue reading “Seeking Other Perspectives to Tease Out New Innovations” »

As Drug Development Costs Skyrocket, AI Offers Some Hope

Posted on November 20th, 2017 in Pharma R&D

Last year, researchers from the Tufts Center for the Study of Drug Development published a paper in the Journal of Health Economics that provided an assessment of the current cost for pharmaceutical companies to discover and develop new drugs and biologics. Continue reading “As Drug Development Costs Skyrocket, AI Offers Some Hope” »

Myelo Therapeutics Takes on Unmet Needs in Cancer

Posted on November 17th, 2017 in Pharma R&D

Many pharmaceutical and biotechnology start-ups have been founded for the purpose of taking on unmet needs. It has often been difficult for the larger, more established pharma companies to focus on these narrower problems, so the leaner, scrappier start-ups are putting their passion and brainpower to the challenges that have yet to be tackled. Continue reading “Myelo Therapeutics Takes on Unmet Needs in Cancer” »

  1. 1
  2. 2
  3. 3
  4. 18